CTRI/2018/01/011454已完成2 期
A single arm, single centered clinical study on healthy human subjects, to evaluate the suitability of the product regime on sensitive scalp.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Volunteer in generally in good health.
- •2) Volunteer with sensitive scalp condition.
- •3) Healthy female volunteer between 19 to 35 years of age (both inclusive)
- •4) Volunteer willing to give a written informed consent and come for regular observation.
- •5) The volunteer has not participated in a similar clinical investigation in the same past four weeks.
排除标准
- •1) A known history or present condition of an allergic response to any cosmetic products.
- •2) Skin disease (e.g. psoriasis, atopic dermatitis or other cutaneous manifestations on the scalp), which would interfere with the test readings.
- •3) Medications (e.g. Steroids or antihistamines), which would compromise the study.
- •4) Pregnant or lactating.
- •5) Volunteer viewed by the investigator as not being able to complete the study or participating in another study.
研究者
相似试验
尚未招募
Unknown
A multi-center, single-arm clinical study for the efficacy and safety of '10THERMA' on tissue coagulation and skin rejuvenatioFactors influencing health status and contact with health servicesKCT0008709Korean Society for Laser Medicine and Sugery31
已完成
3 期
A study to assess Efficacy and safety of Ayurvedic Kadha in health and immunity related parameters in mild COVID-19 patients.CTRI/2021/03/032072MARC Laboratories Ltd50
进行中（未招募）
1 期
A single-center, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis.EUCTR2017-005065-47-SETikoMed AB15
进行中（未招募）
不适用
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2013-001439-34-DEGenzyme Corporation1,000
进行中（未招募）
1 期
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisEUCTR2013-001439-34-ESGenzyme Corporation1,001